Abstract
High blood pressure is considered one of the major risk factors for heart disease. In addition to evidence of low heart disease and death with adequate control of blood pressure, antihypertensive treatment is still less effective in clinical practice. It is well documented that there is a decrease in cardiovascular events, such as stroke and MI, with potent therapies to combat high blood pressure. This, however, is generally believed to be the result of a phase. This review paper includes and focuses on evidence from clinical trials in support of amlodipine as a first-line anti-hypertensive agent, showing how its unique properties can provide better cardiovascular protection compared to other antihypertensive agents to prevent stroke and cardiovascular disease. Evidence from the many randomized controlled trials presented below shows that amlodipine has excellent efficacy and safety, as a first-rate anti-hypertensive agent not only to control BP but also to safely improve patient outcomes. Patients treated with this drug have benefited as they have fewer hospitals and lower rates of recovery. Its unique mechanism of action leads to a reduction in the development of atherosclerosis. In addition, amlodipine with effective BP control for 24 hours may also be helpful as an adjunct to the treatment of patients with renal impairment by reducing the progression of end-stage renal disease.
Highlights
Calcium channel blockers (CCBs), initially introduced over 3 decades ago for coronary heart disease (CHD), are widely known and used for their efficacy in hypertension (HTN)
The results showed that both monotherapy groups improved their blood pressure in similar ways, with average blood pressures in the 130s/80s for both, the effects of the amlodipine-based regimen were more obvious, especially in the early stages
Long-term follow-up of trials in patients with hypertension where active treatment was compared with placebo, and where blood pressure differences were associated with substantial reductions in cardiovascular events, a carryover effect was seen in the post-trial period along with on average 9% long-term reductions in mortality in the groups previously receiving active treatment[20]
Summary
Calcium channel blockers (CCBs), initially introduced over 3 decades ago for coronary heart disease (CHD), are widely known and used for their efficacy in hypertension (HTN). The VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial was a large randomized, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine that enrolled 15245 patients, ≥ 50 years, who had hypertension (controlled or uncontrolled), and was at a greater risk for any CV events.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
